Market Research Logo

Poxviridae Infections - Pipeline Review, H2 2016

Poxviridae Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Poxviridae Infections - Pipeline Review, H2 2016’, provides an overview of the Poxviridae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poxviridae Infections , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poxviridae Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Poxviridae Infections
    • The report reviews pipeline therapeutics for Poxviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Poxviridae Infections therapeutics and enlists all their major and minor projects
    • The report assesses Poxviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Poxviridae Infections
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Poxviridae Infections
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Poxviridae Infections pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Poxviridae Infections Overview
    Therapeutics Development
    Pipeline Products for Poxviridae Infections - Overview
    Pipeline Products for Poxviridae Infections - Comparative Analysis
    Poxviridae Infections - Therapeutics under Development by Companies
    Poxviridae Infections - Therapeutics under Investigation by Universities/Institutes
    Poxviridae Infections - Pipeline Products Glance
    Late Stage Products
    Early Stage Products
    Poxviridae Infections - Products under Development by Companies
    Poxviridae Infections - Products under Investigation by Universities/Institutes
    Poxviridae Infections - Companies Involved in Therapeutics Development
    Bavarian Nordic A/S
    BioFactura, Inc.
    CEL-SCI Corporation
    Chimerix, Inc.
    China Biologic Products, Inc.
    CJ HealthCare Corp.
    EpiVax, Inc.
    N & N Pharmaceuticals Inc.
    SIGA Technologies, Inc.
    Takeda Pharmaceutical Company Limited
    Tonix Pharmaceuticals Holding Corp.
    Verrica Pharmaceuticals Inc.
    Poxviridae Infections - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (plague + small pox) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    24a - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BA-368 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    brincidofovir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CEL-1000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CJ-40011 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    imatinib mesylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies for Infectious Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Smallpox - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nilotinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NN-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PL-801 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SCV-305 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Molluscum Contagiosum - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    small pox vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    smallpox vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    smallpox vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tecovirimat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    varicella hyperimmune globulins - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VIR-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VIR-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VP-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Poxviridae Infections - Dormant Projects
    Poxviridae Infections - Discontinued Products
    Poxviridae Infections - Product Development Milestones
    Featured News & Press Releases
    Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government
    Apr 25, 2016: SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat
    Mar 17, 2016: SIGA Commences Clinical Study for Intravenous (IV) Formulation of TPOXX
    Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral
    Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral
    Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
    Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene
    Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of $13.0 Million for the Continued Development of Brincidofovir for Smallpox
    Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
    Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million
    May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine
    Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery
    Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of $190 Million
    Dec 23, 2014: Chimerix Provides Recap of 2014 Events
    Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Poxviridae Infections, H2 2016
    Number of Products under Development for Poxviridae Infections - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Poxviridae Infections - Pipeline by Bavarian Nordic A/S, H2 2016
    Poxviridae Infections - Pipeline by BioFactura, Inc., H2 2016
    Poxviridae Infections - Pipeline by CEL-SCI Corporation, H2 2016
    Poxviridae Infections - Pipeline by Chimerix, Inc., H2 2016
    Poxviridae Infections - Pipeline by China Biologic Products, Inc., H2 2016
    Poxviridae Infections - Pipeline by CJ HealthCare Corp., H2 2016
    Poxviridae Infections - Pipeline by EpiVax, Inc., H2 2016
    Poxviridae Infections - Pipeline by N & N Pharmaceuticals Inc., H2 2016
    Poxviridae Infections - Pipeline by SIGA Technologies, Inc., H2 2016
    Poxviridae Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
    Poxviridae Infections - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
    Poxviridae Infections - Pipeline by Verrica Pharmaceuticals Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Poxviridae Infections - Dormant Projects, H2 2016
    Poxviridae Infections - Dormant Projects (Contd..1), H2 2016
    Poxviridae Infections - Dormant Projects (Contd..2), H2 2016
    Poxviridae Infections - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Poxviridae Infections, H2 2016
    Number of Products under Development for Poxviridae Infections - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Top 10 Molecule Types, H2 2016
    Number of Products by Stage and Top 10 Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report